Buprenorphine - Naloxone

Tuesday, 25 November 2008 13:45 - 15:30, Bayside 102

Chair Eric C Strain Johns Hopkins University School of MedicineUnited States
Use of buprenorphine and buprenorphine-naloxone via non-sublingual routes
  • Dr Adam R Winstock, Sydney South West Area Health Service
Comparing jurisdictional approaches to the implementation of buprenorphine-naloxone (Suboxone®) in New South Wales, Victoria, and Western Australia
  • Ms Kristie Mammen, The Langton Centre, South Eastern Sydney and Illawara Area Health Service
Examining interactions of alprazolam in buprenorphine-naloxone and methadone patients
  • Suzanne Nielsen, Turning Point Alcohol and Drug Centre
Switching patients from Subutex to Suboxone
  • Jeremy Hayllar, Queensland Health
Does “client stability” predict the injection of methadone, buprenorphine and buprenorphine-naloxone among opioid substitution treatment clients?
  • Briony Larance, National Drug and Alcohol Research Centre